

Moderator	Colm Leonard, Infex Therapeutics, ex-NICE (UK NHS)
Eligibility criteria needed to ensure diversity in the pipeline	
10:00-10:10	Marco Cavalieri (European Medicines Agency) Key factors for evaluating antimicrobials
10:10-10:20	Sophie Cooper (UK NICE) Eligibility/evaluation criteria in the UK model
10:20-10:35	Q&A
Transferable exclusivity extension vouchers	
10:35-10:45	Pierre Dubois (Toulouse School of Economics) Features of an efficient voucher
10:45-10:55	Tim Wilsdon (Charles River Associates) Review of amendments in the compromise texts
10:55-11:00	Henry Skinner (AMR Action Fund) Investor perceptions
11:00-11:15	Q&A
Milestone Prizes: conditions for viable implementation in the EU	
11:15-11:25	Enrico Baraldi (Uppsala University) Design of an impactful milestone prize
11:25-11:30	Marc Gitzinger (BioVersys) Paying for failure?
11:30-11:45	Q&A
11:45-11:55	Break
Subscriptions and revenue guarantees	
11:55-12:05	Christine Ardal (NIPH Norway / EU-JAMRAI-2) Incentivising Member State participation
12:05-12:10	Jean-Baptiste Perrin (DG HERA) Hurdles in setting-up a pan-EU revenue guarantee
12:10-12:15	David Glover (NHS England) Collaboration across the 4 nations of the United Kingdom
12:15-12:30	Q&A
Transferable Priority Review Voucher (TPRV): conditions for viable implementation in the EU	
12:30-12:40	David Ridley (Duke University) Lessons from implementation in the US, projection in the EU
12:40-12:45	Stefan Schulz (MSD) Value brought by a TPRV in the European market
12:45-13:00	Q&A